Notice of a Pilot Program on Medication Therapy Management Under the TRICARE Program, 56968-56969 [2017-25823]
Download as PDF
<![CDATA[
56968
Federal Register / Vol. 82, No. 230 / Friday, December 1, 2017 / Notices
sradovich on DSK3GMQ082PROD with NOTICES
5510–00–NSH–0080—Stakes/Lath, Survey,
Wood
5510–00–NSH–0081—Stakes/Lath, Survey,
Wood
5510–00–NSH–0082—Stakes/Lath, Survey,
Wood
5510–00–NSH–0083—Stakes/Lath, Survey,
Wood
5510–00–NSH–0084—Stakes/Lath, Survey,
Wood
5510–00–NSH–0085—Stakes/Lath, Survey,
Wood
5510–00–NSH–0086—Stakes/Lath, Survey,
Wood
5510–00–NSH–0087—Stakes/Lath, Survey,
Wood
5510–00–NSH–0088—Stakes/Lath, Survey,
Wood
5510–00–NSH–0089—Stakes/Lath, Survey,
Wood
5510–00–NSH–0090—Stakes/Lath, Survey,
Wood
5510–00–NSH–0091—Stakes/Lath, Survey,
Wood
5510–00–NSH–0092—Stakes/Lath, Survey,
Wood
5510–00–NSH–0093—Stakes/Lath, Survey,
Wood
5510–00–NSH–0094—Stakes/Lath, Survey,
Wood
5510–00–NSH–0095—Stakes/Lath, Survey,
Wood
5510–00–NSH–0096—Stakes/Lath, Survey,
Wood
5510–00–NSH–0097—Stakes/Lath, Survey,
Wood
5510–00–NSH–0101—Stakes/Lath, Survey,
Wood
5510–00–NSH–0102—Stakes/Lath, Survey,
Wood
5510–00–NSH–0103—Stakes/Lath, Survey,
Wood
5510–00–NSH–0104—Stakes/Lath, Survey,
Wood
5510–00–NSH–0105—Stakes/Lath, Survey,
Wood
5510–00–NSH–0106—Stakes/Lath, Survey,
Wood
Mandatory Source of Supply: Siskiyou
Opportunity Center, Inc., Mt. Shasta, CA
Contracting Activity: FOREST SERVICE,
KLAMATH NATIONAL FOREST
NSN—Product Name: 8470–00–NSH–0030—
Improved Oxygen Harness
Mandatory Source of Supply: Employment
Source, Inc., Fayetteville, NC
Contracting Activity: Army Contracting
Command—Aberdeen Proving Ground,
Natick Contracting Division.
Patricia Briscoe,
Deputy Director, Business Operations,
(Pricing and Information Management).
[FR Doc. 2017–25854 Filed 11–30–17; 8:45 am]
BILLING CODE 6353–01–P
VerDate Sep<11>2014
16:44 Nov 30, 2017
Jkt 244001
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary
Advisory Panel; Notice of Federal
Advisory Committee Meeting
Assistant Secretary of Defense
(Health Affairs), Department of Defense.
ACTION: Notice of Federal Advisory
Committee meeting.
AGENCY:
The Department of Defense is
publishing this notice to announce a
Federal Advisory Committee meeting of
the Uniform Formulary Beneficiary
Advisory Panel (hereafter referred to as
the Panel).
DATES: Open to the public on Thursday,
January 4, 2018, from 9:00 a.m. to 12:00
p.m.
ADDRESSES: Naval Heritage Center
Theater, 701 Pennsylvania Avenue NW.,
Washington, DC 20004.
FOR FURTHER INFORMATION CONTACT:
Captain Edward C. Norton, United
States Navy, Designated Federal
Official, Uniform Formulary Beneficiary
Advisory Panel, 7700 Arlington
Boulevard, Suite 5101, Falls Church, VA
22042–5101. Email Address:
dha.ncr.health-it.mbx.baprequests@
mail.mil.
SUMMARY:
This
meeting is being held under the
provisions of the Federal Advisory
Committee Act of 1972 (5 U.S.C.,
Appendix, as amended), the
Government in the Sunshine Act of
1976 (5 U.S.C. 552b, as amended), and
41 CFR 102–3.140 and 102–3.150.
Purpose of Meeting: The Panel will
review and comment on
recommendations made to the Director
of the Defense Health Agency, by the
Pharmacy and Therapeutics Committee,
regarding the Uniform Formulary.
Meeting Agenda:
1. Sign-In
2. Welcome and Opening Remarks
3. Scheduled Therapeutic Class Reviews
(Comments will follow each agenda
item)
a. Weight Loss Agents
b. Oncological Agents: Multiple
Myeloma
c. Prenatal Vitamins
4. Newly Approved Drugs Review
5. Pertinent Utilization Management
Issues
6. Panel Discussions and Vote
Meeting Accessibility: Pursuant to 5
U.S.C. 552b, as amended, and 41 CFR
102–3.140 through 102–3.165, and the
availability of space, this meeting is
open to the public. Seating is limited
and will be provided only to the first
220 people signing-in. All persons must
sign-in legibly.
Written Statements: Pursuant to 41
CFR 102–3.140, the public or interested
organizations may submit written
statements to the membership of the
Panel about its mission and/or the
agenda to be addressed in this public
meeting. Written statements should be
submitted to the Panel’s Designated
Federal Officer (DFO). The DFO’s
contact information can be obtained in
the FOR FURTHER INFORMATION CONTACT
section.
Written comments or statements must
be received by the committee DFO at
least five (5) business days prior to the
meeting so that they may be made
available to the Panel for its
consideration prior to the meeting. The
DFO will review all submitted written
statements and provide copies to all the
committee members.
Dated: November 28, 2017.
Aaron Siegel,
Alternate OSD Federal Register Liaison
Officer, Department of Defense.
[FR Doc. 2017–25899 Filed 11–30–17; 8:45 am]
BILLING CODE 5001–06–P
DEPARTMENT OF DEFENSE
Office of the Secretary
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
Notice of a Pilot Program on
Medication Therapy Management
Under the TRICARE Program
Office of the Secretary,
Department of Defense.
ACTION: Notice of a Pilot Program.
AGENCY:
Per Section 726 of the
National Defense Authorization Act
(NDAA) for Fiscal Year (FY) 2015, the
Department of Defense (DoD) is
implementing a 2-year Pilot Program,
‘‘Pilot Program on Medication Therapy
Management Under TRICARE Program’’.
The Pilot Program will provide
Medication Therapy Management
(MTM) services to promote adherence
and improve medication-related health
outcomes for TRICARE beneficiaries
(Beneficiaries) with more than one
chronic medical condition and taking
more than one medication. The Pilot
Program will be conducted in three
types of pharmacy settings. The intent
of this Pilot Program is to evaluate the
feasibility and desirability of including
MTM as part of the TRICARE Program.
DATES: The demonstration began on
October 1, 2016, and will continue for
no less than two years.
FOR FURTHER INFORMATION CONTACT: Mr.
David W. Bobb, Defense Health Agency,
SUMMARY:
E:\FR\FM\01DEN1.SGM
01DEN1
Federal Register / Vol. 82, No. 230 / Friday, December 1, 2017 / Notices
J–3 Pharmacy Operations Division,
telephone 703–681–2890.
SUPPLEMENTARY INFORMATION:
sradovich on DSK3GMQ082PROD with NOTICES
A. Background
Medicare Part D plans already provide
MTM/clinical pharmacy services to
Medicare beneficiaries at high risk of
medication-related problems. The
design of the DoD Pilot Program will
consider best commercial practices in
providing MTM services.
The value of including clinical
pharmacists on the PCMH care team is
well documented in the literature as
delivering improved outcomes, better
medication adherence, and supports the
tenets of healthcare reform including
enhanced access, improved quality,
reduced cost, and enhanced patient
safety.
Clinical pharmacists play a critical
role in the success of care provided
through the PCMH model. Utilizing
clinical pharmacists has clearly shown
the relationship between pharmacist
involvement and positive patient
outcomes especially in the optimization
of medication therapy, medication
adherence, and the reduction in
polypharmacy users.
B. Description of the Pilot Program
Services will be offered by
pharmacists at three different location
types: (1) MTFs with a pharmacist
embedded supporting a PCMH, (2) MTF
pharmacies for beneficiaries who
receive primary care services from
providers outside an MTF but bring
their prescriptions to the MTF
pharmacy, and (3) pharmacies other
than an MTF. MTM involves a
pharmacist in the review of prescription
history where the pharmacist works
with the patient and their primary care
provider to develop action plans for any
medication-related problems. The
overall goal of MTM is to open a
dialogue with beneficiaries and include
them in medication-related decisionmaking to optimize drug therapy,
reduce medication-related problems,
improve adherence to therapy, and
improve health outcomes. As stated in
Section 726, NDAA FY15, the 2-year
pilot program’s target population will be
beneficiaries who have more than one
chronic medical condition and are
taking more than one medication.
This pilot program will focus
specifically on beneficiaries diagnosed
with at least three chronic medical
conditions and taking multiple
medications. The following chronic
medical conditions will be considered
for this pilot: Alzheimer’s disease,
Chronic Heart Failure, Diabetes,
Dyslipidemia, End-Stage Renal Disease,
VerDate Sep<11>2014
16:44 Nov 30, 2017
Jkt 244001
Hypertension, Respiratory Disease
(Asthma, Chronic Obstructive
Pulmonary Disease [COPD]),
Rheumatoid Arthritis, Post-Traumatic
Stress Syndrome, Depression, and
Polypharmacy. This is consistent with
the intent of Section 726, NDAA FY
2015 of more than one chronic medical
condition and taking more than one
medication. Each site within the three
location types will target an enrollment
of 400 beneficiaries over at least 12
months, but not to exceed 24 months,
providing up to 6 hours of contact per
beneficiary per year.
Selection for Location Type 1 will be
from the existing PCMH empaneled
population. MTM services will be
provided by a pharmacist embedded in
the PCMH. The following facilities will
be included in the pilot program for
Location Type 1: Fort Campbell, Naval
Station Mayport, and Hill Air Force
Base.
Location Type 2 will include
beneficiaries who use MTF pharmacies
but receive medical care from providers
in the purchased care sector.
Beneficiaries will be notified of their
eligibility to participate in the Pilot
Program, and may choose to accept or
decline participation. Beneficiaries
participating in the Pilot Program at this
location type generally do not receive
primary care services from health care
providers at MTFs. The following
facilities will be included in the pilot
program for Location Type 2: Fort
Campbell, Marine Corps Base Camp
Pendleton, and Patrick Air Force Base.
Location Type 3 will provide MTM
services for beneficiaries receiving
medical and pharmaceutical care
outside of an MTF. Beneficiaries will be
notified of their eligibility to participate
in the Pilot Program, and may choose to
accept or decline participation. The
following areas will be included in the
pilot program for Location Type 3:
Denver, Colorado, Orlando, Florida, and
Houston, Texas.
MTM services will be provided by a
pharmacist to beneficiaries empaneled
in the pilot program. Appointments will
be conducted face to face, over the
telephone, and/or by video
conferencing. MTM services will
include a Comprehensive Medication
Review (CMR) consisting of an
assessment of the beneficiary’s
medication regimen, a comprehensive
record of medications, a collaborative
care agreement between the beneficiary
and the pharmacist, communication
with the beneficiary’s healthcare
providers, and documentation with
follow up. CMR is conducted at the
initial visit and annually thereafter.
Interim Targeted Medication Reviews
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
56969
are offered quarterly to monitor
unresolved issues requiring attention
and to determine if new drug therapy
problems have arisen. The pharmacist,
in consultation with the beneficiary,
reviews pertinent medical and
prescription history and develops action
plans to address medication-related
problems.
C. Evaluation
The effect of MTM services on
beneficiary use and outcomes of
prescription medications and the cost of
health care will be evaluated using
established DoD metrics of Per Member
Per Month (PMPM) and Pharmacy
PMPM. Additional measures may
include a review of changes in
utilization of the emergency
department, hospitalization rates and
readmission rates. Beneficiary use and
outcomes of prescription medications
will assess medication adherence and
disease related outcomes measures,
when available.
A report to Congress is required not
later than 30 months after the start of
the Pilot.
Dated: November 27, 2017.
Aaron Siegel,
Alternate OSD Federal Register Liaison
Officer, Department of Defense.
[FR Doc. 2017–25823 Filed 11–30–17; 8:45 am]
BILLING CODE 5001–06–P
DEPARTMENT OF EDUCATION
Notice Inviting Statements of Interest
From Nonprofit Organizations
Interested in Partnering To Expand the
#GoOpen Network
Office of the Secretary,
Department of Education.
ACTION: Notice.
AGENCY:
The Department through the
Office of the Secretary’s Office of
Educational Technology (OET) created
the #GoOpen Network in October of
2015, to support the use of openly
licensed educational resources, by
establishing a network of mentoring
relationships with experienced districts
and States providing support to those
districts that were new to the use of
open resources. To support this work,
OET is seeking to select and partner
with a nonprofit organization or a
consortium of nonprofit organizations to
further expand and enhance the
network. Thus, this notice outlines the
criteria to be used for selecting partner
organizations; invites statements of
interest from nonprofit organizations
interested in partnering to build on and
expand the #GoOpen network; and
SUMMARY:
E:\FR\FM\01DEN1.SGM
01DEN1
]]>Agencies
[Federal Register Volume 82, Number 230 (Friday, December 1, 2017)]
[Notices]
[Pages 56968-56969]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25823]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Notice of a Pilot Program on Medication Therapy Management Under
the TRICARE Program
AGENCY: Office of the Secretary, Department of Defense.
ACTION: Notice of a Pilot Program.
-----------------------------------------------------------------------
SUMMARY: Per Section 726 of the National Defense Authorization Act
(NDAA) for Fiscal Year (FY) 2015, the Department of Defense (DoD) is
implementing a 2-year Pilot Program, ``Pilot Program on Medication
Therapy Management Under TRICARE Program''. The Pilot Program will
provide Medication Therapy Management (MTM) services to promote
adherence and improve medication-related health outcomes for TRICARE
beneficiaries (Beneficiaries) with more than one chronic medical
condition and taking more than one medication. The Pilot Program will
be conducted in three types of pharmacy settings. The intent of this
Pilot Program is to evaluate the feasibility and desirability of
including MTM as part of the TRICARE Program.
DATES: The demonstration began on October 1, 2016, and will continue
for no less than two years.
FOR FURTHER INFORMATION CONTACT: Mr. David W. Bobb, Defense Health
Agency,
[[Page 56969]]
J-3 Pharmacy Operations Division, telephone 703-681-2890.
SUPPLEMENTARY INFORMATION:
A. Background
Medicare Part D plans already provide MTM/clinical pharmacy
services to Medicare beneficiaries at high risk of medication-related
problems. The design of the DoD Pilot Program will consider best
commercial practices in providing MTM services.
The value of including clinical pharmacists on the PCMH care team
is well documented in the literature as delivering improved outcomes,
better medication adherence, and supports the tenets of healthcare
reform including enhanced access, improved quality, reduced cost, and
enhanced patient safety.
Clinical pharmacists play a critical role in the success of care
provided through the PCMH model. Utilizing clinical pharmacists has
clearly shown the relationship between pharmacist involvement and
positive patient outcomes especially in the optimization of medication
therapy, medication adherence, and the reduction in polypharmacy users.
B. Description of the Pilot Program
Services will be offered by pharmacists at three different location
types: (1) MTFs with a pharmacist embedded supporting a PCMH, (2) MTF
pharmacies for beneficiaries who receive primary care services from
providers outside an MTF but bring their prescriptions to the MTF
pharmacy, and (3) pharmacies other than an MTF. MTM involves a
pharmacist in the review of prescription history where the pharmacist
works with the patient and their primary care provider to develop
action plans for any medication-related problems. The overall goal of
MTM is to open a dialogue with beneficiaries and include them in
medication-related decision-making to optimize drug therapy, reduce
medication-related problems, improve adherence to therapy, and improve
health outcomes. As stated in Section 726, NDAA FY15, the 2-year pilot
program's target population will be beneficiaries who have more than
one chronic medical condition and are taking more than one medication.
This pilot program will focus specifically on beneficiaries
diagnosed with at least three chronic medical conditions and taking
multiple medications. The following chronic medical conditions will be
considered for this pilot: Alzheimer's disease, Chronic Heart Failure,
Diabetes, Dyslipidemia, End-Stage Renal Disease, Hypertension,
Respiratory Disease (Asthma, Chronic Obstructive Pulmonary Disease
[COPD]), Rheumatoid Arthritis, Post-Traumatic Stress Syndrome,
Depression, and Polypharmacy. This is consistent with the intent of
Section 726, NDAA FY 2015 of more than one chronic medical condition
and taking more than one medication. Each site within the three
location types will target an enrollment of 400 beneficiaries over at
least 12 months, but not to exceed 24 months, providing up to 6 hours
of contact per beneficiary per year.
Selection for Location Type 1 will be from the existing PCMH
empaneled population. MTM services will be provided by a pharmacist
embedded in the PCMH. The following facilities will be included in the
pilot program for Location Type 1: Fort Campbell, Naval Station
Mayport, and Hill Air Force Base.
Location Type 2 will include beneficiaries who use MTF pharmacies
but receive medical care from providers in the purchased care sector.
Beneficiaries will be notified of their eligibility to participate in
the Pilot Program, and may choose to accept or decline participation.
Beneficiaries participating in the Pilot Program at this location type
generally do not receive primary care services from health care
providers at MTFs. The following facilities will be included in the
pilot program for Location Type 2: Fort Campbell, Marine Corps Base
Camp Pendleton, and Patrick Air Force Base.
Location Type 3 will provide MTM services for beneficiaries
receiving medical and pharmaceutical care outside of an MTF.
Beneficiaries will be notified of their eligibility to participate in
the Pilot Program, and may choose to accept or decline participation.
The following areas will be included in the pilot program for Location
Type 3: Denver, Colorado, Orlando, Florida, and Houston, Texas.
MTM services will be provided by a pharmacist to beneficiaries
empaneled in the pilot program. Appointments will be conducted face to
face, over the telephone, and/or by video conferencing. MTM services
will include a Comprehensive Medication Review (CMR) consisting of an
assessment of the beneficiary's medication regimen, a comprehensive
record of medications, a collaborative care agreement between the
beneficiary and the pharmacist, communication with the beneficiary's
healthcare providers, and documentation with follow up. CMR is
conducted at the initial visit and annually thereafter. Interim
Targeted Medication Reviews are offered quarterly to monitor unresolved
issues requiring attention and to determine if new drug therapy
problems have arisen. The pharmacist, in consultation with the
beneficiary, reviews pertinent medical and prescription history and
develops action plans to address medication-related problems.
C. Evaluation
The effect of MTM services on beneficiary use and outcomes of
prescription medications and the cost of health care will be evaluated
using established DoD metrics of Per Member Per Month (PMPM) and
Pharmacy PMPM. Additional measures may include a review of changes in
utilization of the emergency department, hospitalization rates and
readmission rates. Beneficiary use and outcomes of prescription
medications will assess medication adherence and disease related
outcomes measures, when available.
A report to Congress is required not later than 30 months after the
start of the Pilot.
Dated: November 27, 2017.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2017-25823 Filed 11-30-17; 8:45 am]
BILLING CODE 5001-06-P
